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Reynold Spector1* and Conrad E Johanson2Abstract
The purpose of this review is to discuss the implications of the 2009 discovery of the sixth deoxyribonucleoside
(dN) [5-hydroxymethyldeoxycytidine (hmdC)] in DNA which is the most abundant in neurons. The concurrent
discovery of the three ten-eleven translocation enzymes (TET) which not only synthesize but also oxidize hmdC in
DNA, prior to glycosylase removal and base excision repair, helps explain many heretofore unexplained phenomena
in brain including: 1) the high concentration of ascorbic acid (AA) in neurons since AA is a cofactor for the TET
enzymes, 2) the requirement for reduced folates and the dN synthetic enzymes in brain, 3) continued DNA
synthesis in non-dividing neurons to repair the dynamic formation/removal of hmdC, and 4) the heretofore
unexplained mechanism to remove 5-methyldeoxycytidine, the fifth nucleoside, from DNA. In these processes, we
also describe the important role of choroid plexus and CSF in supporting vitamin homeostasis in brain: especially
for AA and folates, for hmdC synthesis and removal, and methylated deoxycytidine (mdC) removal from DNA in
brain. The nexus linking AA and folates to methylation, hydroxymethylation, and demethylation of DNA is pivotal to
understanding not only brain development but also the subsequent function.
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Choroid plexusIntroduction
For over forty years, we and myriad others have investi-
gated fluid (CSF) production by choroid plexus (CP) [1-3],
ion and pH homeostasis in CSF [4-6], vitamin transport
and homeostasis in CSF and brain [7-11], and DNA
precursor transport/synthesis as well as DNA synthesis in
developing and adult brain [12,13]. The importance of pH
and ionic stability in CSF [14,15] and the extracellular
space (ECS) of brain is immediately apparent: neurons
cannot function properly with perturbations of pH and
ions in CSF and brain ECS [16,17].
The transport and homeostatic mechanisms for
certain vitamins (e.g., ascorbic acid (AA) and folates,
subjects of this review), however, were unusual and
unexpected [7,8,18]. In fact, for these two vitamins,
which are concentrated ~ four times in both animal
and human CSF, the one-hundred-year-old notion of
the CSF as “nourishing liquor” for the brain turned out* Correspondence: mspec007@verizon.net
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article, unless otherwise stated.to be correct [8,18]. The mechanism for this physiologic
process (with AA) was first illustrated by Hammarstrom
[19] who demonstrated auto-radiographically that 14C-AA
is transported from blood into CP, then CSF, next the brain
adjacent to the CSF and finally, slowly, into the deep sub-
stance of the brain [8,19-22]. This route was subsequently
also shown to be the way by which folates enter brain [23].
At that time we hypothesized that AA and folates enter
brain predominantly via this circuitous route rather than
directly via the blood–brain barrier (BBB) because this is
an ontogenetic carry over. See below [23].
Moreover, from the CSF and ECF of brain, neurons
concentrated AA to ~200 times the concentration of blood
(~10 mM versus ~50 μM in plasma). Why do neurons
require so much AA [20,24]? This puzzle has persisted for
decades but, as described below, we now have a convincing
although tentative answer. Similarly, why is there so
much folate, and the enzymes to make the various folate
cofactors in brain, e.g., for DNA synthesis [25,26]?
There is ~25 times more folate in brain than plasma
(0.02 μM). Again, an answer is now presented.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and humans, was that there are comprehensive trans-
port systems and synthetic enzymes to ensure ad-
equate and constant supplies of the precursors for
active and ongoing widespread DNA synthesis in situ
in adult and aged brain [13]. We wondered why, espe-
cially in adult human brain where there is no neuronal
cell division except a 2% annual turnover in the den-
tate gyrus, would there be such a requirement for
DNA synthesis [27]. Could it just be for routine DNA
repair or mitochondrial duplication? This seemed an
inadequate explanation. However, the discovery of
ten-eleven translocation enzymes (TET) enzymes and
5-hydroxymethyldeoxycytidine (hmdC) in brain pro-
vides a partial answer as described below.
The purpose of this review is first to summarize
briefly the transport and homeostatic systems for AA
and folates in CSF and brain, and second the nature of
the DNA precursor transport and enzyme systems in
CP and brain. Following those comments, we then
review the relevant findings and implications, begin-
ning in 2009, of the discovery of the sixth deoxyribo-
nucleoside (dN) in DNA, hydroxymethyldeoxycytidine
(hmdC) [28,29]. We also recapitulate the data showing
more hmdC in neurons (e.g., 0.6% of deoxynucleosides
in nuclear DNA in Purkinje cells and neurons in
general) than in any other cell-type [28]. Moreover,
the amount of hmdC in brain neurons increases with
age [30]. We will also recount the roles of hmdC in
DNA as both a fairly stable marker [like methylated
deoxycytidine (mdC) which makes up ~0.9% of the dN
in DNA] and an unstable regulatory molecule modu-
lating and controlling transcription of hundreds of
genes; and how the discovery of hmdC and its re-
moval, at last, explains the mechanism by which mdC
can be removed from DNA [30-34]. Finally, we will as-
sess the implications of the finding in 2013 that AA
is a cofactor for the three ten-eleven translocation
(TET) enzymes (TET 1–3) that produce and then, in
some cases, oxidize hmdC in DNA prior to its re-
moval, most likely by thymine DNA glycosylase (TDG)
or possibly dC deaminase [34-36]. Subsequent to the
removal of the oxidized hmdC from DNA, the DNA
requires repair by the base excision repair (BER)
mechanism in brain cells, a mechanism that requires
the apparatus for DNA synthesis [31,35,36].
With this new information, we put forward an ex-
planation for why hmdC in neurons helps explain the
necessity for the high concentrations of AA, folate and
the extensive machinery for DNA synthesis in adult and
aged brain. Moreover, these findings have enormous
implications for brain development and maturation
as well as embryonic and adult stem cell research and
cancer [34,35].In order to preclude inappropriate conclusions, we will
be very cautious about placing too much emphasis on
tissue culture and other in vitro results, especially those
done without AA in the medium. For example, Qiao and
May in an elegant study [37] confirmed that in vivo hu-
man brain endothelial cells do not contain the sodium-
dependent vitamin C transporter-2 (termed SVCT-2), the
principal transporter of AA in CP and neurons [38] (see
below). But as the endothelial cells divide in vitro, they
acquire this transporter as do astrocytes which also do not
express SVCT-2 in vivo. Thus, to paraphrase Song and He
[34]: it is crucial to show that events that occur in vitro,
e.g., in tissue culture, “indeed happen in vivo”. Their
words were prophetic since some recent work was not
conducted with AA in the medium for full TET activity;
thus the formation/removal of hmdC in DNA was in-
complete and many results that they and others have
reviewed require reconsideration as discussed below.
Ascorbic acid homeostasis in brain
Fifty years ago, Hughes showed that in AA-deficient
guinea pigs, which like primates cannot synthesize
AA, the brain was the last organ to be depleted of AA
[20,21,39,40]. We now know that this is not due to
lack of AA turnover. This finding helped explain why
in severe human scurvy, CNS function is maintained
as Lind pointed out centuries ago. As noted above,
Hammarstrom [19] reported that AA was transported
into brain via the CP and CSF [20,21]. In humans the
CP is an organ weighing about 2 grams and receives
blood flow at 4 to 5 ml/min/g. The CP epithelial cells,
along with the arachnoid membrane, are the sites of the
blood-CSF barrier [10,41,42]. Like the cerebral endothelial
cells, the CP epithelial cells (not its capillaries) are joined
by restrictive tight junctions [43]. Choroidal tight junctions
are the anatomic substrate of the blood-CSF barrier
(BCSFB) that restricts diffusion of molecules as small as
urea [43]. Therefore, specialized membrane carriers are
needed to move micronutrients (like vitamins), peptides and
ions from blood into CSF [10,41].
Once in CSF, substances can penetrate the CSF-brain in-
terfaces because there is a negligible barrier (gap junctions)
to permeation via diffusion and pulsatile mixing from CSF
into brain [42,44]. However, the process is slow. Some
investigators have questioned whether substances can
penetrate from CSF deep into the substance of the brain,
but we, following Hammarstrom, have shown in rabbits
that AA (m.w. 176) and mannitol (m.w. 182) penetrate
deeply into rabbit brain from injections into ventricular
CSF [22]. Others have shown that the much larger inulin
(m.w. ~5000) can also slowly penetrate from CSF deep into
brain [45].
Following Hammarstrom, we confirmed and extended
his work in rabbits with 14C-AA in vitro and in vivo
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transport into brain via CP-CSF rather than brain capil-
laries. Subsequent elegant work showed that the key AA
transport system in CP is the SVCT-2 [38] that is not
present in astrocytes or cerebral capillaries [24,37,46,47].
The SVCT-2 transporter is present on the basal (blood)
side of the CP and in neurons [46,47]. In vivo, in mam-
mals the CP pumps ~ one-half of the AA in plasma
flowing through the CP into CSF with a step-up in
concentration of ~4 times [48]. In neurons, AA is con-
centrated further by another ~50 times by membrane-
bound SVCT-2. Thus, the concentration of AA in
human plasma, CSF and neurons is ~50, 200 and
10,000 μM, respectively [24]. The validity of this model
is corroborated by the phenotype of SVCT-2 knockout
(KO) mice [49].
For details of AA systems in the CNS, there are recent
reviews by us [8] and others, including a discussion of
AA transport into and release from astrocytes by differ-
ent mechanisms [24,46,47,50,51]. Still unknown is how
AA exits the CP into CSF. However, what is clear is that
the CNS homeostatic system is optimally developed to
minimize fluctuation of the AA concentration in neu-
rons [50]. Thus, at low plasma concentrations, relatively
more AA is pumped into CSF via the CP; at high con-
centrations, relatively less, because the KT (half satur-
ation concentration) of SVCT-2 is close to the plasma
concentration (~50 μM) [8,50]. Moreover, because the
CSF and ECS of brain concentrations of AA are ~4
times higher than the plasma concentration, the SVCT-
2 system in neurons is “saturated” except in extreme
deficiency states [47,50].
Our explanation for the location of the SVCT-2 sys-
tem in CP is that it is a carryover from early develop-
ment when the CP is almost as big as the brain itself,
presumably supplying nutrients to the latter [23]. How-
ever, as the forebrain grew in size, macronutrients like
glucose and amino acids required the development of
specialized carriers like glut-1 at the capillaries of the
BBB. However, a few functions like micronutrient trans-
port (e.g., AA and folate) were retained in CP [23]. Also,
high levels of AA and folate bathing the subventricular
zone where many neurons originate during develop-
ment seem sensible. In elderly humans and Alzheimer’s
disease patients, these CP transport functions remain
normal [48].
Many investigators have offered reasons for the high
concentration of AA in neurons, e.g., to serve as a cofac-
tor for dopamine-β-hydroxylase which requires a milli-
molar concentration of AA for activity, for amidation of
peptides, and for the synthesis of mature collagen [52].
However, these processes only occur in a small number
of neurons (or other cells). Others have speculated that
AA acts as a general antioxidant. In her excellent review,like us, Rice concluded that we do not know why there
is so much AA in neurons [24].
Finally, in experiments analogous to the experiments
with the TET enzymes described below, we studied a
model of sympathetic neurons that synthesize norepin-
ephrine (NE) from dopamine (DA) by DA-β-hydroxylase,
an enzyme that requires millimolar concentrations of AA
as a cofactor [52,53]. The model consisted of pheochro-
mocytoma cells grown in tissue culture stimulated with
nerve growth factor [53]. These cells then develop the
properties of sympathetic neurons, e.g., extend varicose
neurites that contain synaptic vesicles. If AA was added to
the culture medium, NE was synthesized; if AA was left
out, minimal NE was synthesized. In vitro, these cells take
up AA by an active, saturable transport system. Moreover,
the KT for AA uptake into the differentiated cells was
36 μM. In retrospect, the AA carrier in these cells was
almost certainly SVCT-2, the function of which was to
concentrate intracellular AA to millimolar levels so that
DA-β-hydroxylase could synthesize NE from DA (for rele-
vance, see below).
Folate transport into brain via CSF
The folate transport system in CP works similarly to the
AA system, actively pumping methyltetrahydrofolate
(MeTHF), the principal folate in plasma and CSF, from
plasma into CSF [8,18,25,26,54]. Consequently, the
steady-state concentration of MeTHF in CSF is ~2-4
times higher than plasma where ~50-60% of MeTHF is
loosely bound to albumin [55]. In our early studies of
the transport of folate, we discovered and purified the
folate receptor α (FRα) in CP (pigs and humans) that
binds both reduced and oxidized folates (e.g., folic acid)
very tightly [54,56]. Our initial model of FRα, picking
up MeTHF from blood (on the basal side of CP) and
releasing it by facilitated diffusion on the apical side, was
obviously incomplete [23]. How was the tightly-bound
MeTHF released from the FRα [54,56]? This conundrum
was solved in 2006 by Goldman’s group who discovered,
cloned and characterized the proton-coupled folate trans-
porter (PCFT; SLC 46A1) in gut and CP [57,58]. Presently
the current model has CP transporting MeTHF from
plasma into CSF, sequentially, from the vascular side of
CP via membrane-bound FRα that becomes entrapped in
pinched-off intracellular vesicles [18,57]. Then, PCFT
releases the MeTHF from the vesicles into CP epithelial
cytoplasm at pH ~7.1 [59]. Finally, by facilitated diffusion
the MeTHF is released into CSF by the reduced folate
carrier (RFC; SLC 19A1) at the apical side [60].
Several groups have confirmed and extended these ani-
mal findings to human CP and CSF [54,57]. Noteworthy
is that the FRα is absent in cerebral capillaries [61]. Con-
sequently, negligible MeTHF enters brain directly from
blood [62]. Consistent with this model is that human
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ciency (CFD) states, characterized by very low CSF folate
concentrations and severe neurological disease or death
[63-65]. Early treatment with mega-doses of reduced
folates ameliorates CFD, however, and when started early
enough, prevents CNS damage [64]. Evidently sufficient
folate enters the brain to overcome the FRα or PCFT
deficiency.
An acquired CFD, due to antibodies against FRα, can
also be partially overcome by mega-doses of reduced
folates [66]. Such experimental and clinical findings
establish beyond doubt (in humans) the primary role of
the CP in pumping folate from blood into CSF. Although
controversy exists over the exact localization of FRα and
PCFT in CP, however, it is clear that MeTHF is trans-
ported from plasma into CSF via CP [67,68]. Moreover,
FRα-KO mice are not viable [65].
The exact mechanism(s) by which MeTHF enters neu-
rons from CSF is unclear. Such concentrative uptake pre-
sumably involves the RFC present in neurons. In rabbits,
however, unlike AA that turns over in brain relatively
rapidly (t½ ~1 day), the folate turnover is exceedingly
slow. Our best estimate in rabbits is a 7–10 day half-life
[25,26]. A very slow turnover makes the study of brain
MeTHF uptake more challenging.
Recently one group [67] postulated vesicular transport
of MeTHF in FRα-containing vesicles released directly
from CP into CSF, and then transported transependymally
into brain. We think that this model needs substantiation
for several reasons: 1) in earlier studies of 14C-MeTHF
transport from blood to CSF, >73% of all untreated CSF
samples yielded free 14C- MeTHF in column effluent; 2)
untreated human CSF specimens emerge from HPLC col-
umns as free MeTHF, a phenomenon not expected with
vesicle-bound MeTHF [69]; 3) the FRα-containing vesicles
were obtained from immortalized CP cells grown in cul-
ture, which as noted above, are prone to phenomena not
occurring in vivo; 4) the authors do not explain how vesi-
cles travel deep into the brain; and finally 5) the investiga-
tors do not cite the work of Holm et al. (1991) who
extended/confirmed our work with human CP and CSF
[54], demonstrating soluble FRα in human CSF (1 nM).
Normally human CSF contains >40 nM MeTHF. For these
reasons, unless the proponents of CSF vesicular trans-
port provide definitive evidence that CSF, especially hu-
man, contains significant MeTHF in FRα-containing
vesicles and that previous related research is incorrect,
it appears that the unbound MeTHF diffusion/convec-
tion model for CSF described by several investigators
[18,57] is currently the best fit of the collective data.
It is unequivocal that MeTHF is transported via CP
from plasma into CSF by a system ~1/2 saturated at the
normal plasma folate of ~20 nM [25,26]. Also, there is
concurrence about the difficulty in depleting the healthybrain and CSF (with a normal CP) of folates. Although
efficient and stabilizing, the brain homeostatic system for
folates can be overcome by an extreme folate deficiency
state or by a lack of FRα or PCFT in CP.
The origin of DNA precursor molecules in adult brain
A) Role of transport from blood to central nervous
system
In mammals, especially humans, it is clear that deoxyr-
ibonucleoside (dN) triphosphate precursors are predom-
inantly synthesized de novo or salvaged in situ in brain
[13,70]. In human plasma, the mean concentrations of
uridine, hypoxanthine and thymidine are 3.1, 0.6, and
0.2 μM, respectively; in human lumbar CSF, 2.3, 2.5 and
0.06 μM, respectively [70]. The following observations
pertain to human plasma [70]: 1) there was no detectable
(0.1 μM) thymine, cytosine, guanine, cytidine or guanosine;
2) the other dNs present in DNA were also not detectable
(0.1 μM); and 3) adenine and adenosine were present
inconsistently with means of 0.3 and 0.2 μM, respectively.
Thus, although there are weak (facilitated diffusion) sys-
tems for nucleosides and hypoxanthine at the BBB,
except for uridine there is not enough dN and rN in
human plasma to supply brain requirements for DNA
synthesis [13].
In regard to bidirectional transport underlying CSF
homeostasis of nucleotides, it is worth noting that CP
contains a powerful system for removing rN and dN
from CSF in vivo. On the apical, CSF-facing side of CP is
the CNT3 transporter (SLC28a3) that actively and pro-
miscuously clears rN and dN from CSF; the rN and dN
(transported into CP from CSF) are released at the basal
(blood) side of CP by an equilibrative nucleoside trans-
porter (ENT1) [13]. Moreover, the human CSF thymi-
dine concentration is 1/10 that of rabbit and rat [70].
Thus, extrapolating thymidine (or bromodeoxyuridine)
pharmacokinetics from animals to humans is difficult.
For a comprehensive review of the origin of dN in brain,
see [13].
B) In situ salvage/synthesis of dN and DNA in developing
and mature brain
In early work, we were surprised that dihydrofolate
reductase (DHR), an enzymatic reducer of oxidized folates
and dihydrobiopterin, to their tetrahydro derivatives, was
reported as absent in brain in view of the serious toxicity
of intrathecal methotrexate, a potent inhibitor of DHR
[71]. With careful study, we were able to show unequivo-
cally in developing and adult rabbit, rat and human brains
that DHR is widely active. Subsequently we studied (dir-
ectly and indirectly) in developing/mature rabbits and/or
rats the mitochondrial and cytoplasmic forms of the
salvage enzymes: deoxycytidine (dC) kinase and thymidine
kinase (TK) [13]. These kinases are active throughout
brain – even in adult and old animals.
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and thymidylate synthetase [TS] (employing methylene-
THF as a cofactor), were also analyzed [13]; again, these
synthetic enzymes displayed activity even in adult CNS.
To assess activity of thymidylate synthetase in vivo, we
injected 3H-deoxyuridine (dU) into the cerebral ventricles
of temporarily-anesthetized rabbits. The radio-labeled
dU reached brain, where the 3H-dU was converted into
3H-DNA via 3H-thymidine. This established that both the
salvage enzymes (i.e., TK, which converts dU to dU mono-
phosphate) and TS were active in vivo even in older rab-
bits. TS activity in human brain explains the CNS toxicity
of 5-fluorouracil, an inhibitor of TS. It is also fascinating
that neurospheres in vitro require reduced folates and will
not accept thymidine (and salvage of dT by TK) [13]. If
this phenomenon occurs in vivo (i.e., the necessity of re-
quiring thymidine in DNA via TS), it implies that
parenterally-labeled thymidine (or BrdU) misses sites of
DNA synthesis in vivo; see [13] for further discussion of
this point. Moreover, the protective enzyme dUTPase,
which breaks down dUTP (capable of being erroneously
incorporated into DNA), was active in adult and old rabbit
brains [72].
Particularly surprising was the substantial activity of
these enzymes in adult and aged brain. In some cases,
e.g., RR and dUTPase, the enzymes were easily detected
in adult and older brain, but not in liver. Moreover, the
amount of actual DNA synthesis diffusely present in
brain (clearly not for DNA replication since adult hu-
man neurons do not generally divide except in dentate
gyrus [27]), in both the mitochondrial and especially
the nuclear fractions, was unexpected. ‘Why the case’ is
discussed below.
In related studies of brain and liver, we measured the
methionine synthetase (MS) that employs MeTHF and
vitamin B-12 to convert homocysteine to methionine
[73,74]. Although methionine in plasma fluxes into brain
across cerebral capillaries, apparently the blood-borne
supply is insufficient. We established that MS, occurring
in all brain regions, actively converts homocysteine into
methionine in vivo in un-anesthetized adult rabbits [74].
This is a critical reaction because methionine is con-
verted to the S-adenosylmethionine (SAM) that serves
as a methyl donor in myriad reactions – the one of
greatest interest here is the methylation of dC in DNA
by both de novo and maintenance DNA methylases. A
great mystery in biology, both in brain and other tissues,
still remained. How are the folate-dependent methyl
groups (via SAM) as mdC in DNA removed? It was
clear that occasionally they undergo removal. There
were many candidate mechanisms but none had been
established in vivo.
Finally, also surprising was the stability of rN, dN and
base concentrations in plasma and CSF. In adult rabbits,after a four-day fast with only water, there was no change
in mean CSF rN, dN and base concentrations [75]. In
plasma, only uridine changed (a 35% decline). In human
plasma, after a four-day diet of only 100 g/day of glucose,
there was no change in dN, rN or bases (except uridine,
which declined by 36%) [76]. In humans on high-protein
diets, the plasma uridine increases slightly. Therefore,
except for uridine in plasma of rabbits and humans, there
are homeostatic transport mechanisms throughout the
body to maintain a steady concentration of rN, dN and
purine/pyrimidine base concentrations.
The discovery and implications of the hmdC in DNA
In 1983, like many others, we hypothesized that human
DNA contains “abnormal” bases especially in old age
and Alzheimer’s disease. On a sabbatical, one of us (RS)
investigated this question on aged and Alzheimer’s
brains using the best available techniques at that time.
Nothing new was found [77] although hmdC was known
to be in phage DNA.
In 2009, two groups presented unequivocal evidence
that hmdC is indeed present in mammalian DNA, espe-
cially in neurons [28,29]. Moreover, one of these groups
discovered and described the enzymatic mechanisms that
oxidize mdC to hmdC in nuclear DNA, specifically TET
1, 2, and 3 [29]. They showed both Fe++ and α-ketogluta-
rate (α-KG) are TET co-factors. AA also has a co-factoring
reducing role, i.e., to regenerate Fe++ from the Fe+++
formed in the oxidation reaction.
Considerable further work demonstrated that hmdC
could then be oxidized by TET enzymes to 5-formyl dC
(fdC) and then 5-carboxyl dC (cadC) [31-33]. Moreover,
fdC and probably cadC could be removed by TDG with
subsequent DNA repair by BER, thus requiring the four
DNA dN triphosphate precursors [34-36].
A large series of related studies revealed that hmdC
was involved in development, cancer, and transcription
regulation in brain and other tissues. Significantly, the
conundrum about how methyl groups are removed from
mdC in DNA was finally solved by the recognition that
TET enzymes can oxidize mdC in DNA, which could
then be removed [35,36].
An independent remarkable observation was that, when
AA was added to the medium, certain differentiated cells
(e.g., mammalian B cells) could convert to embryonic-like
stem cells capable of forming viable embryos [78]. This
could not be done without AA in the medium. These
groups however did not understand the mechanism. The
critical breakthrough came when two groups established
that AA was a co-factor for the TET enzymes [35,36]. AA
is required to reduce inactive Fe+++ (formed when hmdC
is synthesized in DNA) back to active Fe++, with the for-
mation of DHA (dehydro-AA). DHA can then be reduced
back to AA. This finding is reminiscent of our observation
Figure 1 Distributional route of ascorbic acid (AA) from blood into central nervous system to serve as a co-factor for TET enzymes in
neuronal nuclei: Plasma-borne AA does not permeate the BBB, but is reflected off the inside surface of the capillary endothelium due
to the restriction to diffusion offered by the tight junctions and luminal membrane (upper left). Rather, AA reaches brain by a circuitous
route involving (sequentially) the CP, CSF and ependyma. Thus, AA is transferred (unfilled arrow) from leaky blood vessels in CP through epithelial
cells into ventricular CSF by the sodium-dependent vitamin C transporter 2 (SVCT-2) in the basolateral membrane. From CSF, AA diffuses freely
through permeable gap junctions in the ependyma into brain extracellular fluid. There, AA reaches neurons and is greatly concentrated by the
actively-transporting SVCT-2 in neuronal membranes. Upon accessing the neuronal cytoplasm, AA diffuses to and penetrates the nuclear
membrane. Within the nucleoplasm, AA acts as an essential co-factor for TET (with Fe++ and α-KG) to oxidize certain methyldeoxycytidine
(mdC) molecules in the same-strand DNA to hydroxymethyldeoxycytidine (hmdC). hmdC can be further oxidized and removed from DNA
by thymine DNA glycosylase with subsequent DNA repair as explained in the text. The SVCT-2 transport systems for AA in CP and neurons act not only
as concentrative systems for AA in CSF and neurons but also homeostatic systems that keep the millimolar concentration of AA in
neurons relatively constant.
Spector and Johanson Molecular Brain 2014, 7:3 Page 6 of 9
http://www.molecularbrain.com/content/7/1/3on NGF-treated pheochromocytoma cells that required
AA in the medium to synthesize norepinephrine by
dopamine-β-hydroxylase, an enzyme similar to the TET
enzymes that also require AA [53]. Although iso-ascorbic
acid (isoAA), a widely used anti-oxidant in food, is equally
effective as AA as a cofactor for dopamine-β-hydroxylaseand the TET enzymes, the isoAA has only ~5% the affinity
for SVCT-2 as AA and hence is not transported into CP
or neurons effectively [21].
Finally, to assess the role of AA in vivo in brain, Yin et al.
employed KO mice unable to synthesize AA [36]. They
showed that compared to animals on an AA-supplemented
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much AA in brain) had ~15% less hmdC (P<0.01) in their
cerebral DNA. Given that there are ~12 million hmdC
residues in diploid brain neuronal DNA, this suggests a
decrease of ~2 million hmdC molecules per cell. Finally,
there is now evidence that the TET enzymes and TDG are
targets of micro RNA -29a, thus providing an ever more
complex control of hmdC synthesis and removal in vivo
[79]. It will take considerably more experimentation to
understand the implications of hmdC in DNA, its control
and the profound micronutrient effects on transcription
phenomena. Figure 1 schematically depicts the access of
AA to the neuronal nucleus, by a series of transport steps
for AA from plasma to CP to CSF to brain extracellular
fluid to uptake by the neuron and its nucleus; once in the
nucleus, the AA (along with α-KG, Fe++ and TET) partici-
pates in the ongoing conversion of mdC to hmdC in the
DNA strand.
Implications and vistas
As described herein, we now have sound explanations
for: 1) the need for active powerful systems in CP to
concentrate AA and folates in CSF for ‘nourishment’ of
neurons, 2) the high concentrations of AA and folates
in neurons, and 3) the exquisite control of the CSF
transport, salvage, and formation of the precursors of
DNA synthesis in adult and aged mammalian brain, a
tissue with relatively few dividing cells. As Minor et al.
[35] postulated for cells such as neurons, with high
levels of TET and hmdC in DNA, there would be a need
for substantial concentrations of AA. This prescient
suggestion was confirmed in vivo [36], as described
above. Moreover, the explanation for the activation of
hundreds of genes in cells grown in tissue culture with
AA in the medium (versus controls with minimal AA)
is now clear. Copious AA is required for optimal TET
activity in the synthesis and removal of hmdC. More-
over, the removal of mdC would presumably activate
many quiescent genes [35,36].
A second set of implications is tied to multiple effects
of these findings on: the current methods such as DNA
sequencing and “reading” of nuclear DNA (never mind
the problem of ‘normal’ human and tumor mosaicism),
the current conduct of genome-wide association studies
that do not ‘dissect out’ mdC and hdmC in DNA, the
use of certain restriction enzymes whose function in the
face of hmdC needs investigation, and the ability of
certain DNA-binding proteins and small RNA’s to bind
to hmdC in DNA. This is just a smattering of questions
and issues raised by the establishment of hmdC in DNA.
Such queries are especially pertinent for neuronal DNA
with its relatively large amount of hmdC.
A third implication is the challenge to the notion that in
non-dividing cells, like neurons, the DNA sits in a relativelystatic state. This view is challenged by the finding of
dynamic hmdC in DNA. The potential implications are
profound: we suggest that these discoveries may lead to a
better understanding of heretofore mysterious processes
like memory and consciousness. Molecular tools are avail-
able to expedite the tremendous amount of work needed to
obtain a full understanding of dynamic neuronal DNA. In a
decade or two, the entire view of epigenetic physiology and
neurogenetics could be revolutionized by the seminal find-
ings of neuronal hmdC, the TET enzymes and the role of
AA and folates as essential co-factors in brain nucleotide
metabolism and DNA synthesis.
Finally, the work described in this explanatory review
shows the inestimable value of anatomical, molecular,
biochemical, physiological and pharmacological research
of brain and CSF homeostatic systems. Almost certainly,
this elucidation of brain physiology and cell biology will
prompt incredible advances in the diagnosis and poten-
tially epigenetic treatment of disease, including a better
understanding of memory and even consciousness. The
scientific door is now open and there is a clear and prom-
ising way forward.
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